Here's how to get your hands on the hottest clothing, shoes, and accessories launches of 2025, according to our PEOPLE Style ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 million below the low end of the company’s prior guidance and includes $3.5 ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers.

Eli Lilly shares climbed 32% last year but have slumped more than 16% since October after the company reported third quarter sales of the two drugs below Wall Street’s expectations, prompting ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in sales could portend weaker long-term potential for this market. Lilly is positioned to remain the ...

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates.

Eli Lilly (LLY) shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year. The maker of weight-loss drugs Mounjaro and Zepbound said sales of the drugs grew ...

(Reuters) -Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed ...

Eli Lilly’s (LLY) shares slumped over 8% on Tuesday after the company projected fourth-quarter sales of its weight-loss drug Zepbound and diabetes treatment Mounjaro to fall short of Wall Street ...